{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:09:45Z","timestamp":1789060185509,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>We aimed to evaluate the safety and efficacy of TS-1 adjuvant chemotherapy in Taiwanese patients with gastric cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We included in this study patients with locally advanced gastric cancer who received adjuvant TS-1 or 5-fluorouracil chemotherapy after curative surgery and extended lymph node dissection between 1 June 2008 and 31 December 2012 at Chang Gung Memorial Hospital. Patient characteristics, tumor features, safety profiles and compliance with TS-1 treatment were retrospectively analyzed from medical charts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Forty patients received adjuvant chemotherapy with TS-1 and 193 with 5-fluorouracil within the study period. The 1- and 2-year overall survival rates were 90.6% and 87% in the TS-1 group and 95.4% and 86.8% in the 5-fluorouracil group (<jats:italic>P<\/jats:italic>\u2009=\u20090.34). The 1- and 2-year disease-free survival rates were 90.6% and 74.7% in the TS-1 group and 88% and 75.7% in the 5-fluorouracil group (<jats:italic>P<\/jats:italic>\u2009=\u20090.66). In the TS-1 group, tumor recurrence was more frequent in those with &gt;15 metastatic lymph nodes than \u226415. Overall, 78.9%, 74.3%, 62.1% and 56% of patients underwent TS-1 treatment for at least 3, 6, 9 and 12\u00a0months, respectively. The most common adverse events of TS-1 were skin hyperpigmentation (55%), diarrhea (27.5%), dizziness (27.5%) and leucopenia (20%). Severe adverse events (SAEs; grade III or IV toxicity) were diarrhea (7.5%), stomatitis (7.5%), leukopenia (5%), vomiting (2.5%), anorexia (2.5%) and dizziness (2.5%). Patients who underwent total gastrectomy had a significantly greater risk of TS-1-related SAEs than patients who underwent subtotal gastrectomy (40% versus 8%, <jats:italic>P<\/jats:italic>\u2009=\u20090.014).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The incidence of SAEs during TS-1 therapy was more common in Taiwanese patients with gastric cancer who underwent total gastrectomy compared with those who underwent subtotal gastrectomy. Clinicians must be aware of and able to manage these SAEs to maximize patient compliance with adjuvant TS-1.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1477-7819-11-287","type":"journal-article","created":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T14:02:08Z","timestamp":1383314528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment"],"prefix":"10.1186","volume":"11","author":[{"given":"Wen-Chi","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Lun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng-Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Te","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chih","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shin","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,1]]},"reference":[{"issue":"2","key":"1934_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Canc J Clin. 2011, 61 (2): 69-90. 10.3322\/caac.20107.","journal-title":"CA Canc J Clin"},{"key":"1934_CR2","unstructured":"Health Registry Annual Report 2009, Republic of China. 2011, Taipei City, Taiwan, R.O.C: Bureau of Health Promotion, Department of Health, Executive Yuan"},{"key":"1934_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(06)70623-4","volume":"7","author":"CW Wu","year":"2006","unstructured":"Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J: Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006, 7: 309-315. 10.1016\/S1470-2045(06)70623-4.","journal-title":"Lancet Oncol"},{"key":"1934_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(10)70070-X","volume":"11","author":"I Songun","year":"2010","unstructured":"Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010, 11: 439-449. 10.1016\/S1470-2045(10)70070-X.","journal-title":"Lancet Oncol"},{"key":"1934_CR5","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/sj.bjc.6601761","volume":"90","author":"M Degiuli","year":"2004","unstructured":"Degiuli M, Sasako M, Ponti A, Calvo F: Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Canc. 2004, 90: 1727-1732.","journal-title":"Br J Canc"},{"key":"1934_CR6","first-page":"CD004064","volume":"3","author":"AD Wagner","year":"2010","unstructured":"Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010, 3: CD004064-","journal-title":"Cochrane Database Syst Rev"},{"key":"1934_CR7","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","volume":"24","author":"AD Wagner","year":"2006","unstructured":"Wagner AD, Grothe W, Haerting J, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006, 24: 2903-2909. 10.1200\/JCO.2005.05.0245.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1934_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/00000658-198307000-00004","volume":"198","author":"F Alcobendas","year":"1983","unstructured":"Alcobendas F, Milla A, Estape J, Curto J, Pera C: Mitomycin C as an adjuvant in resected gastric cancer. Ann Surg. 1983, 198 (1): 13-17. 10.1097\/00000658-198307000-00004.","journal-title":"Ann Surg"},{"issue":"3","key":"1934_CR9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/BF01658089","volume":"7","author":"JW Fielding","year":"1983","unstructured":"Fielding JW, Fagg SL, Jones BG, Ellis D, Hockey MS, Minawa A, Brookes VS, Craven JL, Mason MC, Timothy A, Waterhouse JA, Wrigley PF: An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British Stomach Cancer Group. World J Surg. 1983, 7 (3): 390-399. 10.1007\/BF01658089.","journal-title":"World J Surg"},{"issue":"12","key":"1934_CR10","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1200\/JCO.1984.2.12.1366","volume":"2","author":"T Nakajima","year":"1984","unstructured":"Nakajima T, Takahashi T, Takagi K, Kuno K, Kajitani T: Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol. 1984, 2 (12): 1366-1371.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1934_CR11","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1002\/1097-0142(19910515)67:10<2454::AID-CNCR2820671010>3.0.CO;2-2","volume":"67","author":"JE Krook","year":"1991","unstructured":"Krook JE, O'Connell MJ, Wieand HS, Beart RW, Leigh JE, Kugler JW, Foley JF, Pfeifle DM, Twito DI: A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer. 1991, 67 (10): 2454-2458. 10.1002\/1097-0142(19910515)67:10<2454::AID-CNCR2820671010>3.0.CO;2-2.","journal-title":"Cancer"},{"issue":"11","key":"1934_CR12","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1200\/JCO.1995.13.11.2757","volume":"13","author":"M Lise","year":"1995","unstructured":"Lise M, Nitti D, Marchet A, Sahmoud T, Buyse M, Duez N, Fiorentino M, Dos Santos JG, Labianca R, Rougier P: Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol. 1995, 13 (11): 2757-2763.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1934_CR13","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/BF02307081","volume":"2","author":"JS Macdonald","year":"1995","unstructured":"Macdonald JS, Fleming TR, Peterson RF, Berenberg JL, McClure S, Chapman RA, Eyre HJ, Solanki D, Cruz AB, Gagliano R, Estes NC, Tangen CM, Rivkin S: Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group Study. Ann Surg Oncol. 1995, 2 (6): 488-494. 10.1007\/BF02307081.","journal-title":"Ann Surg Oncol"},{"issue":"9175","key":"1934_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(99)01048-X","volume":"354","author":"T Nakajima","year":"1999","unstructured":"Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, Goto M: Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet. 1999, 354 (9175): 273-277. 10.1016\/S0140-6736(99)01048-X.","journal-title":"Lancet"},{"issue":"12","key":"1934_CR15","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1200\/JCO.2003.06.103","volume":"21","author":"A Nashimoto","year":"2003","unstructured":"Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S, Gastric Cancer Surgical Study Group, Japan Clinical Oncology Group: Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206\u20131. J Clin Oncol. 2003, 21 (12): 2282-2287. 10.1200\/JCO.2003.06.103.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1934_CR16","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.2010.534","volume":"303","author":"X Paoletti","year":"2010","unstructured":"Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M, GASTRIC (Global Advanced\/Adjuvant Stomach Tumor Research International Collaboration) Group: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010, 303 (17): 1729-1737.","journal-title":"JAMA"},{"issue":"1","key":"1934_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/bjs.6408","volume":"96","author":"P Sun","year":"2009","unstructured":"Sun P, Xiang JB, Chen ZY: Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg. 2009, 96 (1): 26-33. 10.1002\/bjs.6408.","journal-title":"Br J Surg"},{"issue":"12","key":"1934_CR18","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/bjs.5996","volume":"94","author":"T Nakajima","year":"2007","unstructured":"Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, Fujiya T, Inada T, Sasako M, Ohashi Y, National Surgical Adjuvant Study of Gastric Cancer Group: Randomized controlled trial of adjuvant uracil\u2013tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg. 2007, 94 (12): 1468-1476. 10.1002\/bjs.5996.","journal-title":"Br J Surg"},{"issue":"18","key":"1934_CR19","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K, ACTS-GC Group: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007, 357 (18): 1810-1820. 10.1056\/NEJMoa072252.","journal-title":"N Engl J Med"},{"issue":"9813","key":"1934_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirz\u00e9n F, Noh SH, CLASSIC Trial Investigators: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012, 379 (9813): 315-321. 10.1016\/S0140-6736(11)61873-4.","journal-title":"Lancet"},{"issue":"1","key":"1934_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/PL00011681","volume":"1","author":"Japanese Gastric Cancer Association","year":"1998","unstructured":"Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma \u2013 2nd English edition. Gastric Canc. 1998, 1 (1): 10-24.","journal-title":"Gastric Canc"},{"issue":"33","key":"1934_CR22","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011, 29 (33): 4387-4393. 10.1200\/JCO.2011.36.5908.","journal-title":"J Clin Oncol"},{"key":"1934_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4","volume-title":"AJCC Cancer Staging Manual","author":"FL Greene","year":"2002","unstructured":"Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M: AJCC Cancer Staging Manual. 2002, New York: Springer"},{"issue":"17","key":"1934_CR24","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.2010.534","volume":"303","author":"The Gastric (Global Advanced\/Adjuvant Stomach Tumor Research International Collaboration) Group","year":"2010","unstructured":"The Gastric (Global Advanced\/Adjuvant Stomach Tumor Research International Collaboration) Group: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010, 303 (17): 1729-1737.","journal-title":"JAMA"},{"issue":"10","key":"1934_CR25","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1200\/JCO.1993.11.10.1879","volume":"11","author":"N Wolmark","year":"1993","unstructured":"Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from national surgical adjuvant breast and bowel project protocol C-03. J Clin Oncol. 1993, 11 (10): 1879-1887.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1934_CR26","first-page":"2000","volume":"5","author":"K Hirata","year":"1999","unstructured":"Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Canc Res. 1999, 5 (8): 2000-2005.","journal-title":"Clin Canc Res"},{"issue":"15","key":"1934_CR27","first-page":"2253","volume":"24","author":"T Taguchi","year":"1997","unstructured":"Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, Furue H, Kurihara M, Ota K, Suga S, Ariyoshi Y, Takai S, Shimoyama T, Toge T, Takashima S, Sugimachi K, Hara Y, Fujita H, Kimura K, Saito T, Tsukagoshi S, Nakao I: Phase I study of S-1. S-1 study group. Gan To Kagaku Ryoho. 1997, 24 (15): 2253-2264.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"15","key":"1934_CR28","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1158\/1078-0432.CCR-04-0469","volume":"10","author":"QS Chu","year":"2004","unstructured":"Chu QS, Hammond LA, Schwartz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK: Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Canc Res. 2004, 10 (15): 4913-4921. 10.1158\/1078-0432.CCR-04-0469.","journal-title":"Clin Canc Res"},{"issue":"1","key":"1934_CR29","first-page":"134","volume":"9","author":"PM Hoff","year":"2003","unstructured":"Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R: Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28\u00a0days in patients with solid tumors. Clin Canc Res. 2003, 9 (1): 134-142.","journal-title":"Clin Canc Res"},{"issue":"7","key":"1934_CR30","first-page":"2116","volume":"8","author":"SJ Cohen","year":"2002","unstructured":"Cohen SJ, Leichman CG, Yeslow G, Beard M, Proefrock A, Roedig B, Damle B, Letrent SP, DeCillis AP, Meropol NJ: Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Canc Res. 2002, 8 (7): 2116-2122.","journal-title":"Clin Canc Res"},{"issue":"14","key":"1934_CR31","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1200\/JCO.2000.18.14.2772","volume":"18","author":"CJ van Groeningen","year":"2000","unstructured":"van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, Turner SL, Swart MS, Pinedo HM, Hanauske AR, Giaccone G: Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol. 2000, 18 (14): 2772-2779.","journal-title":"J Clin Oncol"},{"issue":"28","key":"1934_CR32","doi-asserted-by":"publisher","first-page":"6957","DOI":"10.1200\/JCO.2005.01.917","volume":"23","author":"JA Ajani","year":"2005","unstructured":"Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005, 23 (28): 6957-6965. 10.1200\/JCO.2005.01.917.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1934_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3322\/caac.20004","volume":"59","author":"K Ruddy","year":"2009","unstructured":"Ruddy K, Mayer E, Partridge A: Patient adherence and persistence with oral anticancer treatment. CA Canc J Clin. 2009, 59 (1): 56-66. 10.3322\/caac.20004.","journal-title":"CA Canc J Clin"},{"issue":"5","key":"1934_CR34","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3892\/ol.2012.882","volume":"4","author":"H Tsujimoto","year":"2012","unstructured":"Tsujimoto H, Horiguchi H, Hiraki S, Yaguchi Y, Takahata R, Kumano I, Yoshida K, Matsumoto Y, Ono S, Yamamoto J, Hase K: Tolerability of adjuvant chemotherapy with S-1 after curative resection in patients with stage II\/III gastric cancer. Oncol Lett. 2012, 4 (5): 1135-1139.","journal-title":"Oncol Lett"},{"key":"1934_CR35","doi-asserted-by":"crossref","unstructured":"Aoyama T, Yoshikawa T, Shirai J, Hayashi T, Yamada T, Tsuchida K, Hasegawa S, Cho H, Yukawa N, Oshima T, Rino Y, Masuda M, Tsuburaya A: Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol. doi:10.1245\/s10434-012-2776-6","DOI":"10.1245\/s10434-012-2776-6"},{"key":"1934_CR36","doi-asserted-by":"crossref","unstructured":"Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, Cho H, Tsuburaya A: Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer. Gastric Canc. doi:10.1007\/s10120-012-0158-1","DOI":"10.1007\/s10120-012-0158-1"},{"issue":"4","key":"1934_CR37","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00280-012-1935-6","volume":"70","author":"JH Jeong","year":"2012","unstructured":"Jeong JH, Ryu MH, Ryoo BY, Lee SS, Park I, Lee SH, Kim KC, Yook JH, Oh ST, Kim BS, Kang YK: Safety and feasibility of adjuvant chemotherapy with S-1 in Korean patients with curatively resected advanced gastric cancer. Canc Chemother Pharmacol. 2012, 70 (4): 523-529. 10.1007\/s00280-012-1935-6.","journal-title":"Canc Chemother Pharmacol"},{"issue":"6","key":"1934_CR38","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00280-010-1416-8","volume":"67","author":"JS Chen","year":"2011","unstructured":"Chen JS, Chao Y, Hsieh RK, Cheng AL, Chen PM, Chiou TJ, Chao TY, Yeh KH, Chen LT, Whang-Peng J: A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan. Canc Chemother Pharmacol. 2011, 67 (6): 1281-1289. 10.1007\/s00280-010-1416-8.","journal-title":"Canc Chemother Pharmacol"},{"issue":"2","key":"1934_CR39","first-page":"104","volume":"7","author":"T Kinoshita","year":"2004","unstructured":"Kinoshita T, Nashimoto A, Yamamura Y, Okamura T, Sasako M, Sakamoto J, Kojima H, Hiratsuka M, Arai K, Sairenji M, Fukushima N, Kimura H, Nakajima T: Feasibility study of adjuvant chemotherapy with S-1 (TS-1: tegafur, gimeracil, oteracil potassium) for gastric cancer. Gastric Canc. 2004, 7 (2): 104-109.","journal-title":"Gastric Canc"}],"updated-by":[{"DOI":"10.1186\/1477-7819-11-310","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T00:00:00Z","timestamp":1387238400000}}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7819-11-287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T18:46:17Z","timestamp":1630608377000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/1477-7819-11-287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1934"],"URL":"https:\/\/doi.org\/10.1186\/1477-7819-11-287","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,1]]},"assertion":[{"value":"9 April 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"287"}}